New Drug may Destroy Early Cancer Cells

An introduction of a new drug can cut down the growth of cancer cells at their early stages as per new research.

Research conducted by leading cancer metabolism researchers at Stony Brook University, Paul M. Bingham and Zuzana Zachar, is showing promise in this approach with their clinical investigation of a new class of compounds that disrupt cancer cell mitochondrial metabolism.

Japanese Mushroom Extract Kills Cervical-cancer Causing Virus
Japanese mushroom extract active hexose correlated compound (AHCC) kills off HPV, human papillomavirus (HPV) in cervical cancer cells, say researchers.

The lead compound of a new chemical class with a novel mechanism, called CPI-613, attacks two key cancer cell building block targets in one shot to stop tumor growth.

Discoveries by Drs. Bingham, Zachar and colleagues at Stony Brook University led to a technology for the design of drugs that disrupt cancer metabolism.

In collaboration with Cornerstone Pharmaceuticals, they are evaluating the basic mechanisms of actions behind this class of agents.

Genetic Cause of Rare Type of Ovarian Cancer Discovered
Researchers have uncovered the cause of a rare type of ovarian cancer. The findings of the study are published in Natural Genetics.

In 2008, initial stage (phase I) Food and Drug Administration (FDA)-approved clinical trials of anti-cancer compounds began. As the exclusive licensee, Cornerstone is sponsoring the clinical trials, which have now moved into phase II.

The latest research findings in the paper highlights the results of cultured cell studies by the research team in support of the phase II clinical trials.

Third-Hand Smoke Compound Damages DNA and Increases Cancer Risk
Researchers have revealed that one compound from third-hand smoke, which forms when second-hand smoke reacts with indoor air, damages DNA and sticks to it in a way that could cause cancer.

Bingham said that his team discovered that CPI-613 acts as a 'cocktail of one,' meaning the single agent kills cancer cells selectively by simultaneously attacking two crucial metabolic enzymes in cancer cells, and each by a different mechanism.

The critical clinical implication of this duel mechanism of action is that unlike other current anti-cancer agents, CPI-613 has the capacity to attack tumor metabolism more robustly than single-target agents and be less vulnerable to evolved drug resistance, Bingham said.

Dr. Bingham added that CPI-613's two-pronged attack on this cancer cell cycle efficiently and selectively induces cancer cell death in a variety of cancers, including solid tumors and also in leukemia and lymphoma.

The agent attacks and deactivates two lipoate-using enzymes that are major entry points for energy and carbon into the mitochondrial citric acid cycle of the cancer cell.

The study is published in Cancer and Metabolism.

Source-ANI